Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 11/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 3/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218164 | 0.78 | ADRA1A (0.52) | ADRA1AADRA1DADRA1BADRA2ANISCH | |
| SCHEMBL4372649 | 0.74 | ADRA1A (0.65) | ADRA1AADRA1DADRA1BADRA2ACYP19A1 | |
| SCHEMBL1758237 | 0.73 | MAPT (0.54) | ACHECYP19A1KDM4EMEN1MAPT | |
| SCHEMBL8058362 | 0.71 | NOS3 (0.57) | ADRA1AADRA1DADRA1BADRA2ANISCH | |
| Hydrochloric Acid SCHEMBL8104231 | 0.70 | NOS3 (0.56) | ADRA1AADRA1DADRA1BADRA2ANISCH | |
| SCHEMBL30785363 | 0.70 | ACHE (0.55) | ACHECYP19A1MAPTMETAP1 | |
| SCHEMBL2345374 | 0.70 | ACHE (0.55) | ACHECYP19A1MAPTMETAP1 | |
| SCHEMBL966691 | 0.69 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2A | |
| SCHEMBL31484206 | 0.69 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2A | |
| SCHEMBL10826589 | 0.68 | ADRA1A (0.40) | ADRA1AACHECYP19A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934241-B1 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL SCIENT IND RES (IN) | 2012-11-14 | — | — | EP | claimed |
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-05-28 | — | — | US | claimed |
| EP-1934241-A2 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007031833-A2 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-03-22 | — | — | WO | claimed |
| US-8361996-B2 | Imidazolyl substituted steroidal and indan-1-one derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2013-01-29 | — | — | US | disclosed |
| EP-1934241-B1 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL SCIENT IND RES (IN) | 2012-11-14 | — | — | EP | disclosed |
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-1934241-A2 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007031833-A2 | NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | NR5A1, NR3C2, CYP17A1 | ADRA1A 219/4885ADRA1D 207/4885ADRA1B 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.